On December 10, Biogen/Eisai’s controversial Alzheimer’s treatment aducanumab was filed for regulatory approval in Japan. It’s unclear whether Japanese regulators…
COMMENTARY
Can Pharmas and Wholesalers Work to Dispel “Negative Primary Margins on Sales”?
Pharmaceutical wholesalers saw their earnings deteriorate in the April-September first half of FY2014. While their topline faltered on the market’s rapid shift to cheap generic drugs, profits also sagged because of a poor performance by high-margin off-patent branded medicines, called…
To read the full story
COMMENTARY
- Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
- Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near
December 28, 2020
- Generic Makers Reorganizing Manufacturing Sites; Leveraging Their Strengths to Survive
October 23, 2020
- IPOs or Sale? Employee Motivation Depends on Exit Strategies of Investment Funds
September 16, 2020
- Sumitomo Dainippon Aims at 100 Billion Yen Sales from “Frontier Business,” Making Challenge Beyond Drugs
September 9, 2020
With a tumultuous year heading towards a close, let us share the 10 most-read stories on PHARMA JAPAN in 2020. With 2020 being a biennial drug price revision year, our global readers apparently had their eyes riveted on which products…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
As we navigate the lingering effects of the global pandemic, one thing is unmistakably clear - change is here. We’ve changed, and so have our companies. The entire workplace has transformed, but it’s not always a change for the better.…